Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

Tanios S. Bekaii-Saab,Alexander Starodub,Bassel F. El-Rayes,Safi Shahda,Bert H. O’Neil,Anne M. Noonan,Walid Labib Shaib,Wahid Hanna,Sameh Mikhail,Anterpreet S. Neki,Yue Chang,Xiaoshu Dai,Wei Li,Emily Brooks,Cindy Oh,Laura Borodyansky,Chiang Li

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

2018

Tanios S. Bekaii-Saab
Alexander Starodub
Bassel F. El-Rayes
Safi Shahda
Bert H. O’Neil
Anne M. Noonan
Walid Labib Shaib
Wahid Hanna
Sameh Mikhail
Anterpreet S. Neki
Yue Chang
Xiaoshu Dai
Wei Li
Emily Brooks
Cindy Oh
Laura Borodyansky
Chiang Li

4110Background: NAPA is an oral investigational agent, hypothesized to inhibit cancer stemness pathways, including STAT3 pathway implicated in cancer stem-cell viability. We report updated data in ...

Keywords:

Nab-paclitaxel
Cancer
Pathology
Cancer research
Metastatic Pancreatic Adenocarcinoma
NAPA
Napabucasin
Gemcitabine
Medicine
STAT3

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations